DE69509628T2 - N-terminal chemisch modifizierte protein-zusammensetzungen und methoden - Google Patents
N-terminal chemisch modifizierte protein-zusammensetzungen und methodenInfo
- Publication number
- DE69509628T2 DE69509628T2 DE69509628T DE69509628T DE69509628T2 DE 69509628 T2 DE69509628 T2 DE 69509628T2 DE 69509628 T DE69509628 T DE 69509628T DE 69509628 T DE69509628 T DE 69509628T DE 69509628 T2 DE69509628 T2 DE 69509628T2
- Authority
- DE
- Germany
- Prior art keywords
- methods
- chemically modified
- modified protein
- protein compositions
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/321,510 US5824784A (en) | 1994-10-12 | 1994-10-12 | N-terminally chemically modified protein compositions and methods |
PCT/US1995/001729 WO1996011953A1 (en) | 1994-10-12 | 1995-02-08 | N-terminally chemically modified protein compositions and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69509628D1 DE69509628D1 (de) | 1999-06-17 |
DE69509628T2 true DE69509628T2 (de) | 1999-09-16 |
Family
ID=23250903
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69509628T Expired - Lifetime DE69509628T2 (de) | 1994-10-12 | 1995-02-08 | N-terminal chemisch modifizierte protein-zusammensetzungen und methoden |
DE69533556T Revoked DE69533556T2 (de) | 1994-10-12 | 1995-02-08 | N-terminal modifizierte Polypeptide, und Herstellungsprozess |
DE2002199044 Pending DE10299044I1 (de) | 1994-10-12 | 1995-02-08 | n-Terminal chemisch modifizierte Protein-Zusammensetzungen und Methoden |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69533556T Revoked DE69533556T2 (de) | 1994-10-12 | 1995-02-08 | N-terminal modifizierte Polypeptide, und Herstellungsprozess |
DE2002199044 Pending DE10299044I1 (de) | 1994-10-12 | 1995-02-08 | n-Terminal chemisch modifizierte Protein-Zusammensetzungen und Methoden |
Country Status (20)
Country | Link |
---|---|
US (7) | US5824784A (de) |
EP (5) | EP1564219A1 (de) |
JP (8) | JP3177251B2 (de) |
KR (2) | KR100248111B1 (de) |
CN (4) | CN101381409B (de) |
AT (2) | ATE179991T1 (de) |
CA (3) | CA2472085A1 (de) |
DE (3) | DE69509628T2 (de) |
DK (1) | DK0733067T3 (de) |
ES (2) | ES2224197T3 (de) |
GR (1) | GR3030526T3 (de) |
HK (2) | HK1008826A1 (de) |
IL (3) | IL112585A (de) |
LU (1) | LU91006I2 (de) |
MX (1) | MX9602259A (de) |
NL (1) | NL300106I2 (de) |
NZ (1) | NZ281469A (de) |
PT (1) | PT822199E (de) |
WO (1) | WO1996011953A1 (de) |
ZA (1) | ZA951008B (de) |
Families Citing this family (549)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE135370T1 (de) * | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US20020177688A1 (en) * | 1988-12-22 | 2002-11-28 | Kirin-Amgen, Inc., | Chemically-modified G-CSF |
US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
DE69521880T2 (de) * | 1994-02-08 | 2002-01-03 | Amgen Inc | Orales verabreichungssystem von chemischmodifizierten proteinen g-csf |
US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
US20030053982A1 (en) * | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
CA2204726A1 (en) * | 1994-11-09 | 1996-12-27 | Robin E. Offord | Functionalized polymers for site-specific attachment |
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
EP0858343B1 (de) | 1995-11-02 | 2004-03-31 | Schering Corporation | Kontinuierliche, niedrigdosierte zytokine-infusionstherapie |
US5908621A (en) * | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
EP2002846B1 (de) | 1996-12-06 | 2017-01-25 | Amgen Inc. | Kombinationstherapie mit einem IL-1-Inhibitor zur Behandlung von IL-1-vermittelten Krankheiten |
AU5773798A (en) * | 1997-01-29 | 1998-08-18 | Polymasc Pharmaceuticals Plc | Pegylation process |
ATE469166T1 (de) | 1997-06-06 | 2010-06-15 | Kyowa Hakko Kirin Co Ltd | Chemisch modifizierte polypeptide |
DE69838552T2 (de) * | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | Derivate des wachstumshormons und verwandte proteine |
US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
US6017876A (en) * | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
US5985263A (en) * | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US5981709A (en) * | 1997-12-19 | 1999-11-09 | Enzon, Inc. | α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same |
SK286217B6 (sk) | 1998-04-28 | 2008-05-06 | Laboratoires Serono Sa | Polyol-interferón-ß konjugát, spôsob jeho výroby a farmaceutický prostriedok s jeho obsahom |
MY129244A (en) * | 1998-05-15 | 2007-03-30 | Schering Corp | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection. |
NL1009601C2 (nl) * | 1998-07-09 | 2000-01-11 | Univ Utrecht | Verbinding welke de binding van een eiwit aan mestcellen kan remmen, toepassing van de verbinding voor de bereiding van een geneesmiddel, een farmaceutisch preparaat, een werkwijze voor het diagnostiseren van een ziekte en een selectiewerkwijze. |
EP1133563A2 (de) * | 1998-07-16 | 2001-09-19 | Hyseq, Inc. | Verfahren und moleküle in bezug zu dc39-artigen polypeptiden |
US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
ES2404074T3 (es) | 1998-08-06 | 2013-05-23 | Mountain View Pharmaceuticals, Inc. | Conjugados de peg-oxidasa de urato y su uso |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
TR200101087T2 (tr) * | 1998-10-16 | 2001-09-21 | Biogen, Inc. | İnterferon beta-füzyon proteinleri ve kullanımları |
CN1329082C (zh) * | 1998-10-16 | 2007-08-01 | 拜奥根Idec马萨诸塞公司 | 干扰素-β-1a的聚合物缀合物及其使用 |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
KR100719202B1 (ko) | 1998-10-23 | 2007-05-16 | 키린-암젠 인코포레이티드 | MPl 수용체에 결합하는 화합물 및 이를 함유하는 제약학적 조성물 |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
AU2346900A (en) * | 1998-11-30 | 2000-06-19 | Eli Lilly And Company | Erythropoietic compounds |
CA2359345A1 (en) | 1999-01-14 | 2000-07-20 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
ES2204509T3 (es) * | 1999-01-29 | 2004-05-01 | F. Hoffmann-La Roche Ag | Conjugados de gcsf. |
SI1157037T1 (en) * | 1999-01-29 | 2003-12-31 | F. Hoffmann-La Roche Ag | Gcsf conjugates |
WO2000051626A1 (fr) * | 1999-03-01 | 2000-09-08 | Kyowa Hakko Kogyo Co., Ltd. | Preparations de g-csf modifiees chimiquement |
US6485718B1 (en) | 1999-04-13 | 2002-11-26 | Pharmacia Corporation | Site specific ligation of proteins to synthetic particles |
US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US8106098B2 (en) * | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
US7074878B1 (en) * | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
WO2001051510A2 (en) | 2000-01-10 | 2001-07-19 | Maxygen Holdings Ltd | G-csf conjugates |
US6831158B2 (en) * | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
US6646110B2 (en) | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
WO2001058935A2 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
US7049761B2 (en) * | 2000-02-11 | 2006-05-23 | Altair Engineering, Inc. | Light tube and power supply circuit |
PT1129720E (pt) | 2000-02-29 | 2004-08-31 | Pfizer Prod Inc | Factor estimulador de colonias de granulocitos estabilizado |
US20020064820A1 (en) * | 2000-03-13 | 2002-05-30 | Jean-Michel Dayer | Apo-A-I regulation of T-cell signaling |
WO2001076639A2 (en) * | 2000-04-06 | 2001-10-18 | Pharmacia Corporation | Chemically-modified myelopoietin conjugates |
US6586398B1 (en) * | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
CA2406390A1 (en) * | 2000-04-14 | 2001-10-25 | University Of South Carolina Research Foundation | Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase |
DK1290013T3 (da) | 2000-04-21 | 2006-06-26 | Amgen Inc | Apo-A1/All-peptidderivater |
US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
JP2004502783A (ja) * | 2000-07-12 | 2004-01-29 | グリフォン セラピューティクス,インコーポレーテッド | ケモカイン受容体モジュレーター、その産生および利用方法 |
US7118737B2 (en) * | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
SK2772003A3 (en) * | 2000-09-08 | 2003-10-07 | Gryphon Therapeutics Inc | Synthetic erythropoiesis stimulating proteins |
ATE516820T1 (de) | 2000-09-29 | 2011-08-15 | Schering Corp | Pegyliertes interleukin 10 |
AU2001290312A1 (en) * | 2000-10-16 | 2002-04-29 | Chugai Seiyaku Kabushiki Kaisha | Peg-modified erythropoietin |
ES2382636T3 (es) * | 2000-10-31 | 2012-06-12 | Surmodics Pharmaceuticals, Inc. | Método para producir composiciones para la administración mejorada de moléculas bioactivas |
AU2002212108A1 (en) * | 2000-11-02 | 2002-05-15 | Maxygen Aps | Single-chain multimeric polypeptides |
CN1321134C (zh) * | 2000-11-23 | 2007-06-13 | 赵剑 | 一种生物活性蛋白质的非均一制品及其制备方法 |
DE60140693D1 (en) * | 2000-12-14 | 2010-01-14 | Amylin Pharmaceuticals Inc | Ankheiten |
US7053150B2 (en) * | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
TW593427B (en) * | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
CA2431964C (en) * | 2000-12-20 | 2013-09-10 | F. Hoffmann-La Roche Ag | Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
HUP0402041A2 (hu) * | 2001-02-06 | 2005-01-28 | Merck Patent Gmbh | Csökkentett immunogenitású, módosított granulocita-kolonizációt stimuláló faktor (G-CSF) |
EP1234583A1 (de) * | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-Konjugate des HGF-NK4 |
YU48703A (sh) | 2001-02-27 | 2006-05-25 | Maxygen Aps | Novi interferonu beta-slični molekuli |
US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
WO2002088318A2 (en) * | 2001-04-30 | 2002-11-07 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
US7247618B2 (en) * | 2001-04-30 | 2007-07-24 | Tripathi Rajavashisth | Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling |
BR0209546A (pt) | 2001-05-11 | 2004-06-29 | Amgen Inc | Composição de matéria, dna, vetor de expressão, célula hospedeira, e, métodos para tratar uma doença autoimune mediada pelas células b, lúpus, um câncer mediado pelas células b, e linfoma de células b |
DE60229958D1 (de) * | 2001-06-28 | 2009-01-02 | Mountain View Pharmaceuticals | Polymerstabilisierte proteinasen |
ATE468862T1 (de) | 2001-07-11 | 2010-06-15 | Maxygen Inc | G-csf konjugate |
US20040077835A1 (en) * | 2001-07-12 | 2004-04-22 | Robin Offord | Chemokine receptor modulators, production and use |
IL160965A0 (en) * | 2001-10-05 | 2004-08-31 | Intermune Inc | Method of treating hepatitis virus infection with a multiphasic interferon delivery profile |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
US6908963B2 (en) * | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
PT1436012T (pt) | 2001-10-18 | 2018-03-27 | Nektar Therapeutics | Conjugados poliméricos de antagonistas de opióides |
WO2003043651A1 (en) * | 2001-11-19 | 2003-05-30 | Kyowa Hakko Kogyo Co., Ltd. | Drug mobilizing pluripotent stem cells from tissue into peripheral blood |
US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
CN1608079A (zh) * | 2001-11-20 | 2005-04-20 | 法玛西雅公司 | 化学修饰的人生长激素缀合物 |
KR100480432B1 (ko) * | 2001-12-04 | 2005-04-06 | 선바이오(주) | G-csf와 폴리에틸렌글리콜 유도체의 배합체 |
JP2005517648A (ja) * | 2001-12-07 | 2005-06-16 | インターミューン インコーポレイテッド | 肝炎ウイルス感染症を治療するための組成物および方法 |
US7838619B2 (en) * | 2002-01-14 | 2010-11-23 | The General Hospital Corporation | Biodegradable polyketal polymers and methods for their formation and use |
KR100964411B1 (ko) | 2002-01-18 | 2010-06-15 | 바이오겐 아이덱 엠에이 인코포레이티드 | 생물학적 활성 화합물과 컨쥬게이팅되는 잔기를 갖는 폴리알킬렌 글리콜 |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
US20030191056A1 (en) * | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
US20030199464A1 (en) * | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
WO2003105763A2 (en) * | 2002-06-14 | 2003-12-24 | Amylin Pharmaceuticals, Inc. | Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof |
US20040002451A1 (en) * | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
WO2004009774A2 (en) * | 2002-07-19 | 2004-01-29 | Amgen Inc. | Protein conjugates with a water-soluble biocompatible, biogradable polymer |
AU2003254023A1 (en) * | 2002-07-19 | 2004-02-09 | The General Hospital Corporation | Oxime conjugates and methods for their formation and use |
WO2004019866A2 (en) | 2002-08-28 | 2004-03-11 | Immunex Corporation | Compositions and methods for treating cardiovascular disease |
US7157546B2 (en) | 2002-09-09 | 2007-01-02 | Nektar Therapeutics Al, Corporation | Water-soluble polymer alkanals |
US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
JP2004196770A (ja) * | 2002-10-24 | 2004-07-15 | Effector Cell Institute Inc | 樹状細胞前駆体の血中レベル上昇剤 |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7314613B2 (en) | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
PA8588901A1 (es) * | 2002-11-20 | 2005-02-04 | Pharmacia Corp | Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparacion |
US9125880B2 (en) * | 2002-12-26 | 2015-09-08 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
GEP20084487B (en) * | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof |
EP1577323B1 (de) | 2002-12-26 | 2013-07-10 | Takeda Pharmaceutical Company Limited | Metastinderivat und verwendung davon |
US8034900B2 (en) * | 2002-12-30 | 2011-10-11 | Amylin Pharmaceuticals, Inc. | Water-soluble thioester and selenoester compounds and methods for making and using the same |
US7803362B2 (en) * | 2003-01-24 | 2010-09-28 | Synageva Biopharma Corp. | Glycosylated interferon alpha |
EP1597278A4 (de) * | 2003-02-26 | 2006-03-22 | Intermune Inc | Zusammensetzungen von polyethylenglycolmodifiziertem interferon und verfahren zu deren anwendung |
WO2004078127A2 (en) * | 2003-02-28 | 2004-09-16 | Intermune, Inc. | Continuous delivery methods for treating hepatitis virus infection |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
BRPI0408116B1 (pt) | 2003-03-05 | 2022-09-20 | Halozyme, Inc | Polipeptídeos de hialuronidase solúveis conjugados a polímero, composições farmacêuticas compreendendo polipeptídeos ph20 solúveis, seus usos e processo de preparação, e ácidos nucléicos que codificam polipeptídeos de hialuronidase solúveis |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
NZ542094A (en) | 2003-03-14 | 2008-12-24 | Neose Technologies Inc | Branched polymer conjugates comprising a peptide and water-soluble polymer chains |
MXPA05010411A (es) * | 2003-03-28 | 2006-05-31 | Biopolymed Inc | Material activo biologicamente conjugado con polimeros biocompatibles con el complejo 1:1, metodo de preparacion del mismo y composicion farmaceutica que lo contienen. |
US20060134736A1 (en) * | 2003-03-28 | 2006-06-22 | Jacobs John W | Human growth hormone conjugated with biocompatible polymer |
AU2004227937B2 (en) | 2003-03-31 | 2007-09-20 | Xencor, Inc | Methods for rational pegylation of proteins |
US7642340B2 (en) | 2003-03-31 | 2010-01-05 | Xencor, Inc. | PEGylated TNF-α variant proteins |
US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
WO2006127896A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
CN101514223B (zh) | 2003-04-11 | 2017-03-01 | 安特里阿比奥有限公司 | 位点特异性蛋白质偶联物的制备方法 |
ES2340494T3 (es) | 2003-04-15 | 2010-06-04 | Glaxosmithkline Llc | Mutantes de sustitucion de il-18 humana y sus conjugados. |
ES2328640T3 (es) | 2003-04-18 | 2009-11-16 | Biogen Idec Ma Inc. | Neublastina conjugada con un polimero glicosilada. |
CA2525647A1 (en) | 2003-05-16 | 2005-02-24 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
CA2533702C (en) | 2003-07-22 | 2012-05-22 | Nektar Therapeutics Al, Corporation | Method for preparing functionalized polymers from polymer alcohols |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
CA2533512C (en) | 2003-07-25 | 2013-06-11 | Amgen Inc. | Antagonists and agonists of ldcam and methods of use |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
PL1666496T3 (pl) * | 2003-08-25 | 2014-08-29 | Toray Industries | Kompozyt interferonu beta |
GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
BRPI0414017B8 (pt) | 2003-09-17 | 2021-05-25 | Nektar Therapeutics Al Corp | pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços. |
BRPI0414571A (pt) * | 2003-09-22 | 2006-11-07 | Boehringer Ingelheim Int | peptìdeos macrocìclicos ativos contra o vìrus da hepatite c |
ES2831379T3 (es) | 2003-10-09 | 2021-06-08 | Ambrx Inc | Derivados poliméricos para la modificación selectiva de proteínas |
CA2542179A1 (en) | 2003-10-10 | 2005-04-21 | Novo Nordisk A/S | Il-21 derivatives |
EP2327723A3 (de) | 2003-10-10 | 2012-06-27 | Xencor, Inc. | Proteinbasierte TNF-alpha-Varianten zur Behandlung von mit TNF-alpha zusammenhängenden Erkrankungen |
JP4584260B2 (ja) | 2003-10-14 | 2010-11-17 | インターミューン・インコーポレーテッド | Hcv複製阻害剤としての大環状カルボン酸およびアシルスルホンアミド |
EP2633866A3 (de) | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Kombinationstherapie |
US7407973B2 (en) * | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
US7220407B2 (en) * | 2003-10-27 | 2007-05-22 | Amgen Inc. | G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction |
EP1725572B1 (de) | 2003-11-05 | 2017-05-31 | AGCT GmbH | Makromolekulare nukleotidverbindungen und methoden zu deren anwendung |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
WO2005053730A1 (ja) * | 2003-12-05 | 2005-06-16 | Kirin Beer Kabushiki Kaisha | 末期心不全治療剤 |
WO2005067963A1 (en) * | 2003-12-23 | 2005-07-28 | Intermune, Inc. | Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
EP1765853B1 (de) | 2004-01-08 | 2015-10-28 | ratiopharm GmbH | O-Glykosylierung von G-CSF Peptiden |
CA2549851C (en) * | 2004-01-21 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis c virus |
US8778880B2 (en) | 2004-02-02 | 2014-07-15 | Ambrx, Inc. | Human growth hormone modified at position 35 |
EP2417980A1 (de) | 2004-02-11 | 2012-02-15 | Amylin Pharmaceuticals Inc. | Hybridpolypeptide mit auswahlbaren Eigenschaften |
US8603969B2 (en) | 2004-02-11 | 2013-12-10 | Amylin Pharmaceuticals, Llc | Pancreatic polypeptide family motifs and polypeptides comprising the same |
US8076288B2 (en) * | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
CA2556339A1 (en) * | 2004-03-01 | 2005-09-15 | David Ray Filpula | Interferon-beta polymer conjugates |
US20050215710A1 (en) * | 2004-03-23 | 2005-09-29 | Gegg Colin V Jr | Chemically modified protein compositions and methods |
JP2008505853A (ja) | 2004-04-13 | 2008-02-28 | クインテセンス バイオサイエンシーズ インコーポレーティッド | 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体 |
EP1586334A1 (de) * | 2004-04-15 | 2005-10-19 | TRASTEC scpa | G-CSF Konjugate mit PEG |
BRPI0511196A (pt) | 2004-05-19 | 2007-12-04 | Maxygen Inc | polipeptìdeo isolado ou recombinante, conjugado, composição, célula hospedeira, vetor, métodos para preparar um polipeptìdeo, para preparar um conjugado, para reduzir o número de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna hcv, dna hbv e rna hiv no soro de um paciente infectado com hcv, hbv e hiv, e, uso do polipeptìdeo, do conjugado ou da composição |
US20060018875A1 (en) * | 2004-06-14 | 2006-01-26 | Blatt Lawrence M | Interferon compositions and methods of use thereof |
CA2568952C (en) | 2004-06-18 | 2019-05-21 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
PE20091567A1 (es) | 2004-06-25 | 2009-11-03 | Takeda Pharmaceutical | Derivados de metastina en el tratamiento del cancer |
JP2008509889A (ja) * | 2004-06-30 | 2008-04-03 | イージェン コーポレーション | ペグ化インターフェロンα−1b |
US8143380B2 (en) * | 2004-07-08 | 2012-03-27 | Amgen Inc. | Therapeutic peptides |
WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
WO2006091231A2 (en) | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
CN101123978B (zh) | 2004-08-19 | 2012-12-12 | 比奥根艾迪克Ma公司 | 神经胚素变体 |
PT1786454E (pt) | 2004-08-19 | 2010-08-18 | Biogen Idec Inc | Variantes de neublastina |
WO2006031811A2 (en) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
AU2005286662B2 (en) | 2004-09-23 | 2011-10-06 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
EP3061461A1 (de) * | 2004-10-29 | 2016-08-31 | ratiopharm GmbH | Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf) |
AU2005306894B2 (en) | 2004-11-05 | 2011-11-24 | Northwestern University | Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders |
BRPI0518559A2 (pt) | 2004-12-13 | 2008-11-25 | Amylin Pharmaceuticals Inc | motivos da famÍlia do polipetÍdeo pancreÁtico, polipeptÍdeos e mÉtodos compreendendo os mesmos |
DK2399893T3 (en) | 2004-12-22 | 2018-10-08 | Ambrx Inc | COMPOSITIONS CONTAINING, INVOLVING PROCEDURES, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES |
KR20070090023A (ko) | 2004-12-22 | 2007-09-04 | 암브룩스, 인코포레이티드 | 변형 인간 성장 호르몬 |
SG161210A1 (en) | 2004-12-22 | 2010-05-27 | Ambrx Inc | Methods for expression and purification of recombinant human growth hormone |
AU2005322019B2 (en) | 2004-12-22 | 2010-08-26 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
EP1674113A1 (de) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Konjugate von insulinähnlichem Wachstumfaktor-1 und Poly(Ethylenglykol) |
ATE541934T1 (de) * | 2004-12-22 | 2012-02-15 | Ambrx Inc | Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon |
ES2449195T3 (es) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Factor estimulante de colonias de granulocitos glicopegilado |
RU2007132188A (ru) | 2005-01-25 | 2009-03-10 | Селл Терапьютикс, Инк. (Us) | Конъюгаты биологически активных белков, имеющие модифицированное время полужизни in vivo |
CN101119743B (zh) * | 2005-01-31 | 2012-09-26 | 株式会社Eci | 免疫增强剂 |
US7402730B1 (en) | 2005-02-03 | 2008-07-22 | Lexicon Pharmaceuticals, Inc. | Knockout animals manifesting hyperlipidemia |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
MX2007009760A (es) | 2005-02-11 | 2007-11-07 | Amylin Pharmaceuticals Inc | Polipeptidos del analogo e hibrido del peptido inhibidor gastrico con propiedades seleccionables. |
WO2006094530A1 (en) * | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
WO2007010552A2 (en) * | 2005-03-17 | 2007-01-25 | Serum Institute Of India Limited | N- terminal peg conjugate of erythropoietin |
DE602006008456D1 (de) | 2005-03-31 | 2009-09-24 | Amylin Pharmaceuticals Inc | Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen |
JP2008534640A (ja) | 2005-04-05 | 2008-08-28 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | タンパク質の機能部位またはエピトープの遮蔽方法 |
WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
ES2538357T3 (es) | 2005-04-11 | 2015-06-19 | Crealta Pharmaceuticals Llc | Formas variantes de urato oxidasa y uso de las mismas |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
CA2607651A1 (en) | 2005-05-18 | 2007-04-19 | Maxygen, Inc. | Evolved interferon-alpha polypeptides |
JP2008545754A (ja) * | 2005-06-01 | 2008-12-18 | アルザ・コーポレーシヨン | ポリエチレングリコール試薬をアシル化するためのバイオコンジュゲーション反応 |
MX2007015156A (es) * | 2005-06-01 | 2008-02-15 | Maxygen Holdings Ltd | Polipeptidos g-csf pegilados y metodos para la produccion de los mismos. |
WO2007009208A1 (en) * | 2005-06-02 | 2007-01-25 | Cangene Corporation | Poly(ethylene glocol) modified human gm-csf with increased biological activity |
EP1893229B1 (de) * | 2005-06-03 | 2011-10-19 | Ambrx, Inc. | Verbesserte humane interferon-moleküle und ihre verwendungen |
KR100694994B1 (ko) * | 2005-06-13 | 2007-03-14 | 씨제이 주식회사 | 사람 과립구 콜로니 형성인자 동종체 |
US20090042790A1 (en) * | 2005-06-13 | 2009-02-12 | Nastech Pharmaceutical Company Inc. | Transmucosal delivery of peptide derivatives |
MX2007016068A (es) | 2005-06-17 | 2008-03-10 | Novartis Ag | Uso de sanglifehrina en hcv. |
JP5335422B2 (ja) | 2005-06-17 | 2013-11-06 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 少なくとも1つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化 |
US7695710B2 (en) * | 2005-06-20 | 2010-04-13 | Pepgen Corporation | Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs |
AU2006262151A1 (en) * | 2005-06-20 | 2007-01-04 | Pepgen Corporation | Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau |
US8568705B2 (en) * | 2005-07-18 | 2013-10-29 | Nektar Therapeutics | Method for preparing branched functionalized polymers using branched polyol cores |
KR100735784B1 (ko) * | 2005-07-20 | 2007-07-06 | 재단법인 목암생명공학연구소 | 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물 |
JP5249028B2 (ja) | 2005-07-25 | 2013-07-31 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新規大環状阻害剤 |
WO2007015591A1 (en) * | 2005-08-02 | 2007-02-08 | Cheil Industries Inc. | Epoxy resin composition for packaging semiconductor device |
CN101257926A (zh) * | 2005-08-04 | 2008-09-03 | 尼克塔治疗亚拉巴马公司 | G-csf部分与聚合物的轭合物 |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
CA2617649A1 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US7632823B2 (en) | 2005-08-18 | 2009-12-15 | Ambrx, Inc. | Compositions of tRNA and uses thereof |
DK1971362T3 (en) | 2005-08-19 | 2015-01-26 | Amylin Pharmaceuticals Llc | Exendin for treating diabetes and reducing body weight |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
DK1999129T3 (da) | 2005-10-11 | 2011-02-07 | Intermune Inc | Forbindelser og fremgangsmåder til inhibering af replikationen af hepatitis C-virus |
WO2007047303A2 (en) * | 2005-10-12 | 2007-04-26 | Alvine Pharmaceuticals, Inc. | Pegylated glutenase polypeptides |
JP5905184B2 (ja) | 2005-10-13 | 2016-04-20 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. | 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物 |
US20080171696A1 (en) * | 2005-10-21 | 2008-07-17 | Avigenics, Inc. | Pharmacodynamically enhanced therapeutic proteins |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
CN101291684A (zh) * | 2005-10-21 | 2008-10-22 | 阿维季尼克斯股份有限公司 | 甘醇化和糖基化的禽类来源的治疗性蛋白 |
WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
RS51998B (en) * | 2005-11-08 | 2012-04-30 | Ambrx Inc. | ACCELERATORS FOR MODIFICATION OF NON-NATURAL AMINO ACIDS AND NON-NATURAL AMINO ACID POLYPEPTIDES |
TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
WO2007059312A2 (en) * | 2005-11-16 | 2007-05-24 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
EP1968635B1 (de) * | 2005-12-14 | 2014-09-17 | Ambrx, Inc. | Zusammensetzungen und Verfahren mit und Verwendung von nicht-natürlichen Aminosäuren und Polypeptiden |
US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US20070190127A1 (en) | 2005-12-30 | 2007-08-16 | Mingdong Zhou | Extended release of neuregulin for improved cardiac function |
DK1985303T3 (da) | 2006-01-12 | 2013-02-25 | Kitasato Daiichi Sankyo Vaccine Co Ltd | Oral sammensætning indeholdende interferon-alpha |
CN100475270C (zh) * | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
US20070179094A1 (en) | 2006-01-31 | 2007-08-02 | Bayer Schering Pharma Ag | Modulation of MDL-1 activity for treatment of inflammatory disease |
KR101513732B1 (ko) | 2006-02-21 | 2015-04-21 | 넥타르 테라퓨틱스 | 분할된 분해가능한 폴리머 및 이로부터 제조된 컨주게이트 |
TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
US8278421B2 (en) | 2006-03-20 | 2012-10-02 | Xoma Techolology Ltd. | Human antibodies specific for gastrin materials and methods |
WO2007115150A2 (en) * | 2006-03-31 | 2007-10-11 | Centocor, Inc. | Binding partners with immunoglobulin domains modified to have extended half-life |
MX2008013119A (es) | 2006-04-11 | 2008-10-21 | Novartis Ag | Inhibidores de hcv/vih y sus usos. |
US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
EP2029160A2 (de) * | 2006-05-12 | 2009-03-04 | Amylin Pharmaceuticals, Inc. | Verfahren zur wiederherstellung der glykämischen kontrolle |
MX2008014744A (es) | 2006-05-19 | 2009-02-10 | Glycofi Inc | Composiciones de eritrocpoyetina. |
EP2029738A2 (de) | 2006-05-24 | 2009-03-04 | Novo Nordisk Health Care AG | Faktor-ix-analoge mit verlängerter in-vivo-halbwertszeit |
US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
WO2007149594A2 (en) | 2006-06-23 | 2007-12-27 | Quintessence Biosciences, Inc. | Modified ribonucleases |
CA2654661C (en) | 2006-06-26 | 2012-10-23 | Amgen Inc. | Compositions comprising modified lcat and use thereof for treating atherosclerosis |
EP2049151A4 (de) | 2006-07-17 | 2010-03-24 | Quintessence Biosciences Inc | Verfahren und zusammensetzungen zur behandlung von krebs |
US20080274958A1 (en) | 2006-07-21 | 2008-11-06 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
US10300144B2 (en) * | 2006-07-25 | 2019-05-28 | Lipoxen Technologies Limited | N-terminal polysialylation |
GB0615067D0 (en) * | 2006-07-28 | 2006-09-06 | Ttp Communications Ltd | Reconfigurable signal processing scheme |
US8765924B2 (en) | 2006-08-04 | 2014-07-01 | Prolong Pharmaceuticals, Inc. | Modified erythropoietin |
ITMI20061624A1 (it) * | 2006-08-11 | 2008-02-12 | Bioker Srl | Mono-coniugati sito-specifici di g-csf |
US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
ES2393373T3 (es) * | 2006-08-31 | 2012-12-20 | F. Hoffmann-La Roche Ag | Método para la producción de factor-I de crecimiento similar a la insulina |
CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
KR20090051227A (ko) * | 2006-09-08 | 2009-05-21 | 암브룩스, 인코포레이티드 | 척추동물 세포를 위한 하이브리드 서프레서 tRNA |
AU2007292893B2 (en) * | 2006-09-08 | 2012-03-01 | Ambrx, Inc. | Suppressor tRNA transcription in vertebrate cells |
JP5840345B2 (ja) * | 2006-09-08 | 2016-01-06 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 修飾ヒト血漿ポリペプチドまたは修飾ヒトFc足場タンパク質ならびにこれらの利用 |
US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
US20080081031A1 (en) * | 2006-09-28 | 2008-04-03 | Schering Corporation | Use of Pegylated IL-10 to Treat Cancer |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
MX2009003470A (es) * | 2006-10-04 | 2009-04-14 | Novo Nordisk As | Azucares y glicopeptidos pegilados enlazados a glicerol. |
WO2008051383A2 (en) * | 2006-10-19 | 2008-05-02 | Amgen Inc. | Use of alcohol co-solvents to improve pegylation reaction yields |
US7803769B2 (en) | 2006-10-25 | 2010-09-28 | Amgen Inc. | OSK1 peptide analogs and pharmaceutical compositions |
JO3048B1 (ar) | 2006-10-25 | 2016-09-05 | Takeda Pharmaceuticals Co | مشتقات متاستين واستخدامها |
KR101079993B1 (ko) * | 2006-11-17 | 2011-11-04 | 동아제약주식회사 | 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체 |
EP2121743B1 (de) | 2006-11-22 | 2015-06-03 | Bristol-Myers Squibb Company | Gezielte therapeutika auf der basis von manipulierten proteinen für tyrosinkinaserezeptoren, einschliesslich igf-ir |
PT2121751T (pt) | 2006-12-08 | 2017-04-18 | Lexicon Pharmaceuticals Inc | Anticorpos monoclonais contra angptl3 |
EP2111228B1 (de) | 2007-02-02 | 2011-07-20 | Bristol-Myers Squibb Company | 10Fn3 Domain zur Behandlung von Krankheiten begleitet von unerwünschter Angiogenese |
CN101245109B (zh) * | 2007-02-12 | 2011-12-14 | 杭州九源基因工程有限公司 | 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法 |
US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
NZ580030A (en) | 2007-04-03 | 2012-06-29 | Biogenerix Ag | Methods of treatment using glycopegylated g-csf |
JP2008266219A (ja) * | 2007-04-20 | 2008-11-06 | National Institute Of Advanced Industrial & Technology | リジン及びシステイン残基を含まないタンパク質 |
TWI445544B (zh) | 2007-05-01 | 2014-07-21 | Biogen Idec Inc | 增進血管形成之組合物及方法 |
CA2685596A1 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
WO2008153745A2 (en) | 2007-05-22 | 2008-12-18 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
US20110177029A1 (en) * | 2007-06-04 | 2011-07-21 | Novo Nordisk A/S | O-linked glycosylation using n-acetylglucosaminyl transferases |
WO2008154639A2 (en) | 2007-06-12 | 2008-12-18 | Neose Technologies, Inc. | Improved process for the production of nucleotide sugars |
US20110159523A1 (en) * | 2007-06-27 | 2011-06-30 | Cedars-Sinai Medical Center | N-terminal specific chemical labeling for proteomics applications |
EP2489730B1 (de) | 2007-07-26 | 2015-12-30 | Amgen, Inc | Modifizierte Lecithin-Cholesterin-Acyltransferase-Enzyme |
CN101352573B (zh) * | 2007-07-27 | 2011-02-09 | 杭州九源基因工程有限公司 | 聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体 |
WO2009023566A2 (en) | 2007-08-09 | 2009-02-19 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
CL2008002399A1 (es) * | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
CN104689333B (zh) | 2007-08-27 | 2018-05-29 | 拉蒂奥法姆有限责任公司 | G-csf 缀合物的液体制剂 |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
US8758761B2 (en) * | 2007-09-30 | 2014-06-24 | University Of Florida Research Foundation, Inc. | Combination therapies for treating type 1 diabetes |
WO2009048909A1 (en) * | 2007-10-08 | 2009-04-16 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapies |
US8440787B2 (en) | 2007-10-23 | 2013-05-14 | Nektar Therapeutics | Hydroxyapatite-targeting multiarm polymers and conjugates made therefrom |
JP5547083B2 (ja) | 2007-11-20 | 2014-07-09 | アンブルックス,インコーポレイテッド | 修飾されたインスリンポリペプチドおよびそれらの使用 |
WO2009073977A1 (en) * | 2007-12-13 | 2009-06-18 | Biovectra Inc. | Polypeptides modified by protein trans-splicing technology |
NZ586317A (en) * | 2007-12-27 | 2012-10-26 | Baxter Int | Method and compositions for specifically detecting physiologically acceptable polymer molecules |
US20100316702A1 (en) * | 2008-01-08 | 2010-12-16 | The Regents Of The University Of California | Compositions and methods for regulating erythropoeitin expression and ameliorating anemia and stimulating erythropoiesis |
CN102037004A (zh) * | 2008-01-08 | 2011-04-27 | 生物种属学股份公司 | 使用寡糖基转移酶的多肽的糖缀合 |
US20090183503A1 (en) * | 2008-01-18 | 2009-07-23 | Alberto Verdesi | Exhaust apparatus |
PE20140841A1 (es) | 2008-01-18 | 2014-08-03 | Biomarin Pharm Inc | Elaboracion de enzimas lisosomales sulfatasa humanas activas y altamente fosforiladas y sus usos |
NZ620606A (en) | 2008-02-08 | 2015-08-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
US8629104B2 (en) | 2008-02-18 | 2014-01-14 | Jiangsu Hengrui Medicine Co. Ltd. | G-CSF and water-soluble polymer conjugate |
KR101582841B1 (ko) | 2008-02-27 | 2016-01-11 | 노보 노르디스크 에이/에스 | 콘쥬게이트된 인자 viii 분자 |
TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
EP2274624B1 (de) * | 2008-04-03 | 2011-11-09 | F. Hoffmann-La Roche AG | Assays mit pegylierten insulinähnlichen wachstumsfaktoren |
ES2453946T3 (es) * | 2008-04-03 | 2014-04-09 | Biosteed Gene Expression Tech. Co., Ltd. | Hormona del crecimiento modificada con polietilenglicol bicatenario, método de preparación y aplicación de esta |
NZ588638A (en) | 2008-04-14 | 2012-09-28 | Halozyme Inc | Screening method for identifying a subject for treatment with a modified hyaluronidase polypeptides |
TWI394580B (zh) | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
EP2303313B1 (de) | 2008-05-21 | 2015-10-28 | Amylin Pharmaceuticals, LLC | Exendine zur senkung der cholesterin- und triglyceridwerte |
EP2799448A1 (de) | 2008-05-22 | 2014-11-05 | Bristol-Myers Squibb Company | Polyvalente Proteine mit Fibronectin-Gerüstdomänen |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
GB0811743D0 (en) | 2008-06-26 | 2008-07-30 | Hemosol Biopharma Inc | Composition |
EP2307456B1 (de) | 2008-06-27 | 2014-10-15 | Amgen Inc. | Die inhibierung von ang-2 zur behandlung multipler sklerose |
PE20110426A1 (es) | 2008-07-23 | 2011-07-01 | Ambrx Inc | Polipeptidos g-csf bovinos modificados |
EP2314609B1 (de) * | 2008-07-30 | 2016-11-30 | Takeda Pharmaceutical Company Limited | Metastinderivat und verwendung davon |
JP5639585B2 (ja) * | 2008-07-31 | 2014-12-10 | ファーマエッセンティア コーポレイション | ペプチド−ポリマー共役体 |
US8637466B2 (en) | 2008-08-11 | 2014-01-28 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
JP5766118B2 (ja) | 2008-09-11 | 2015-08-19 | ウェルズ ファーゴ バンク ナショナル アソシエイション | ポリマー性アルファ−ヒドロキシアルデヒドおよびケトン反応剤ならびに抱合方法 |
KR101647164B1 (ko) | 2008-09-26 | 2016-08-09 | 암브룩스, 인코포레이티드 | 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도 |
MX357314B (es) * | 2008-09-26 | 2018-07-04 | Ambrx Inc | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales. |
CN102227443B (zh) | 2008-10-01 | 2014-05-14 | 昆特森斯生物科学公司 | 治疗性核糖核酸酶 |
SG195542A1 (en) | 2008-10-10 | 2013-12-30 | Amgen Inc | Fgf21 mutants and uses thereof |
EP2349341B1 (de) | 2008-10-15 | 2013-10-09 | Baxter Healthcare SA | Pegylierung von rekombinanten blutgerinnungsfaktoren in anwesenheit von gebundenen antikörpern |
EP3437661A1 (de) | 2008-10-17 | 2019-02-06 | Baxalta GmbH | Modifizierte blutfaktoren mit einem geringen gehalt an wasserlöslichem polymer |
CA2741209C (en) * | 2008-10-20 | 2016-12-20 | Usv Limited | An improved process for pegylation of proteins |
AU2009307729B2 (en) | 2008-10-21 | 2015-09-17 | Nektar Therapeutics | Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-PEGylation) |
EP2344527A4 (de) * | 2008-10-31 | 2012-04-04 | Amgen Inc | Materialien und verfahren für stammzellenmobilisierung durch einen mehrfach pegylierten granulozyten-kolonie-stimulierenden faktor |
IT1392655B1 (it) | 2008-11-20 | 2012-03-16 | Bio Ker S R L | Site-specific monoconjugated insulinotropic glp-1 peptides. |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
MX2011006110A (es) | 2008-12-09 | 2011-06-24 | Halozyme Inc | Polipeptidos ph20 solubles extendidos y usos de los mismos. |
DK2356467T3 (da) | 2008-12-11 | 2013-10-14 | Baxter Int | Påvisning af fysiologisk acceptable polymermolekyler under anvendelse af nær-infrarød spektroskopi |
DK2379115T3 (da) | 2008-12-17 | 2018-01-29 | Merck Sharp & Dohme | Fremstilling og anvendelse af mono- og di-PEG-IL-10 |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
CA2760674A1 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
AR076541A1 (es) | 2009-05-05 | 2011-06-22 | Amgen Inc | Mutantes de fgf21 y usos del mismo |
CA2758581C (en) | 2009-05-20 | 2022-06-14 | Biomarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
JP2012530493A (ja) | 2009-06-17 | 2012-12-06 | アムジエン・インコーポレーテツド | キメラポリペプチドおよびその使用 |
AU2010262974A1 (en) | 2009-06-19 | 2012-02-02 | Medimmune, Llc | Protease variants |
CZ2011827A3 (cs) | 2009-06-25 | 2012-09-26 | Savient Pharmaceuticals, Inc. | Zpusoby a sady pro predpovídání rizika reakce na infuzi a ztráty odezvy zpusobené protilátkami, monitorováním kyseliny mocové v séru behem lécby pegylovanou urikázou |
US20110027229A1 (en) | 2009-07-31 | 2011-02-03 | Medtronic, Inc. | Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients |
DK2477603T3 (en) | 2009-09-17 | 2016-06-13 | Baxalta Inc | STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF |
EP2480888B1 (de) | 2009-09-25 | 2016-11-30 | XOMA Technology Ltd. | Screening-verfahren |
US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
US20120178914A1 (en) * | 2009-09-25 | 2012-07-12 | Vybion, Inc. | Polypeptide modification |
WO2011050938A1 (de) | 2009-10-26 | 2011-05-05 | Genovoxx Gmbh | Konjugate von nukleotiden und methoden zu deren anwendung |
CA2779244A1 (en) | 2009-10-30 | 2011-05-05 | Boehringer Ingelheim International Gmbh | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
EP2774935B8 (de) | 2009-10-30 | 2017-06-21 | NTF Therapeutics, Inc. | Verbesserte Neurturinmoleküle |
JP2013511287A (ja) | 2009-11-23 | 2013-04-04 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | ポリペプチド・コンジュゲート |
EP2507381A4 (de) | 2009-12-04 | 2016-07-20 | Hoffmann La Roche | Multispezifische antikörper, antikörperanaloge, zusammensetzungen und verfahren |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
CA2784793A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
SG181769A1 (en) | 2009-12-21 | 2012-07-30 | Ambrx Inc | Modified porcine somatotropin polypeptides and their uses |
US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
US20130040888A1 (en) | 2010-02-16 | 2013-02-14 | Novo Nordisk A/S | Factor VIII Molecules With Reduced VWF Binding |
KR101857825B1 (ko) | 2010-03-04 | 2018-05-14 | 피페넥스 인크. | 변성 없이 가용성 재조합 인터페론 단백질을 제조하는 방법 |
NZ603033A (en) | 2010-04-01 | 2014-06-27 | Pfenex Inc | Methods for g-csf production in a pseudomonas host cell |
EP2558497A2 (de) | 2010-04-15 | 2013-02-20 | Amgen Inc. | Menschlicher fgf-rezeptor und beta-klotho-bindeproteine |
WO2011139714A2 (en) | 2010-04-26 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
CN103096911B (zh) | 2010-04-27 | 2018-05-29 | Atyr 医药公司 | 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
WO2011139853A2 (en) | 2010-04-28 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
WO2011150279A2 (en) | 2010-05-27 | 2011-12-01 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
CN103097523B (zh) | 2010-04-29 | 2016-09-28 | Atyr医药公司 | 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
AU2011248457B2 (en) | 2010-04-29 | 2017-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases |
CN102234310B (zh) * | 2010-04-30 | 2017-02-08 | 杭州九源基因工程有限公司 | 一种聚乙二醇修饰蛋白的分离纯化方法 |
US8961961B2 (en) | 2010-05-03 | 2015-02-24 | a Tyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases |
CN105820252B (zh) | 2010-05-03 | 2020-07-21 | Atyr 医药公司 | 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
US8981045B2 (en) | 2010-05-03 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases |
CA2798139C (en) | 2010-05-04 | 2019-09-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex |
US20120135912A1 (en) | 2010-05-10 | 2012-05-31 | Perseid Therapeutics Llc | Polypeptide inhibitors of vla4 |
CN103200953B (zh) | 2010-05-14 | 2017-02-15 | Atyr 医药公司 | 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
NZ603399A (en) | 2010-05-17 | 2014-09-26 | Cebix Inc | Pegylated c-peptide |
AU2011256366C1 (en) | 2010-05-17 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
WO2011150133A2 (en) | 2010-05-26 | 2011-12-01 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
EP2575857B1 (de) | 2010-06-01 | 2018-01-24 | aTyr Pharma, Inc. | Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von lysyl-trna-synthetasen |
US20120123338A1 (en) | 2010-06-16 | 2012-05-17 | Medtronic, Inc. | Damping systems for stabilizing medications in drug delivery devices |
WO2011161644A1 (en) | 2010-06-24 | 2011-12-29 | Panmed Ltd. | Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent |
AU2011289831C1 (en) | 2010-07-12 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
CN102971006A (zh) | 2010-07-15 | 2013-03-13 | 诺沃—诺迪斯克有限公司 | 稳定的因子viii变体 |
ES2661089T3 (es) | 2010-07-20 | 2018-03-27 | Halozyme Inc. | Métodos de tratamiento o prevención de los efectos secundarios adversos asociados con la administración de un agente anti-hialuronano |
AR082319A1 (es) | 2010-07-22 | 2012-11-28 | Biomarin Pharm Inc | Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RU2446173C1 (ru) * | 2010-08-13 | 2012-03-27 | Зао "Биокад" | Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе |
EP2605789B1 (de) | 2010-08-17 | 2019-06-05 | Ambrx, Inc. | Modifizierte relaxinpolypeptide und ihre verwendungen |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
CN103108650A (zh) | 2010-08-25 | 2013-05-15 | Atyr医药公司 | 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
AU2011303916A1 (en) | 2010-09-15 | 2013-03-21 | Novo Nordisk A/S | Factor VIII variants having a decreased cellular uptake |
AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
EA024507B1 (ru) | 2010-09-28 | 2016-09-30 | Амилин Фармасьютикалс, Ллк | Хорошо растворимые лептины |
CN103179974A (zh) | 2010-10-05 | 2013-06-26 | 诺华有限公司 | 丙型肝炎病毒感染的新疗法 |
WO2012048235A1 (en) | 2010-10-08 | 2012-04-12 | Novartis Ag | Vitamin e formulations of sulfamide ns3 inhibitors |
CN102453089B (zh) * | 2010-10-25 | 2014-06-04 | 北京凯因科技股份有限公司 | 重组集成干扰素变异体聚乙二醇偶联物的制备和应用 |
CN103933577B (zh) * | 2010-10-25 | 2014-12-10 | 北京凯因科技股份有限公司 | 重组集成干扰素变异体聚乙二醇偶联物的制备和应用 |
US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
ES2718849T3 (es) | 2010-11-24 | 2019-07-04 | Lexicon Pharmaceuticals Inc | Anticuerpos contra notum pectinacetilesterasa |
CN103221053A (zh) | 2010-11-30 | 2013-07-24 | 诺华有限公司 | 丙型肝炎病毒感染的新疗法 |
CN102485742A (zh) * | 2010-12-02 | 2012-06-06 | 山东新时代药业有限公司 | 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子的制备及分离纯化方法 |
WO2012083197A1 (en) | 2010-12-17 | 2012-06-21 | Nektar Therapeutics | Water-soluble polymer conjugates of topotecan |
WO2012088282A1 (en) | 2010-12-21 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
US20130331443A1 (en) | 2010-12-22 | 2013-12-12 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
US10894087B2 (en) | 2010-12-22 | 2021-01-19 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
ES2634669T3 (es) | 2011-02-08 | 2017-09-28 | Halozyme, Inc. | Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata |
PE20140593A1 (es) | 2011-03-16 | 2014-05-10 | Amgen Inc | Inhibidores potentes y selectivos de nav1.3 y nav1.7 |
US20140171365A1 (en) * | 2011-03-25 | 2014-06-19 | The Trustees Of Columbia University In The City Of New York | Pegylated human hdl particle and process for production thereof |
WO2012130996A1 (en) | 2011-03-31 | 2012-10-04 | Novartis Ag | Alisporivir to treat hepatitis c virus infection |
ES2533213T3 (es) | 2011-04-01 | 2015-04-08 | Novartis Ag | Tratamiento para infección con el virus de hepatitis B solo o en combinación con el virus de hepatitis Delta y enfermedades hepáticas asociadas |
CA2832829A1 (en) | 2011-04-13 | 2012-10-18 | Novartis Ag | Treatment of hepatitis c virus infection with alisporivir |
US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
SG10201902706VA (en) | 2011-06-03 | 2019-04-29 | Xoma Technology Ltd | Antibodies specific for tgf-beta |
MX341448B (es) | 2011-06-17 | 2016-08-19 | Halozyme Inc | Metodos de infusion de insulina subcutanea continua con una enzima que degrada a hialuronano. |
US9993529B2 (en) | 2011-06-17 | 2018-06-12 | Halozyme, Inc. | Stable formulations of a hyaluronan-degrading enzyme |
RU2654231C2 (ru) | 2011-06-28 | 2018-05-17 | Алтернатив Инновейтив Текнолоджиз, Ллц | Способ применения белков теплового шока-70 (бтш70) для повышения выносливости и лечения бтш70-зависимых заболеваний (варианты) |
CA2840552A1 (en) | 2011-07-01 | 2013-01-10 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
EP3088005B1 (de) | 2011-07-05 | 2019-01-02 | biOasis Technologies Inc | P97-antikörperkonjugate |
DK2729160T3 (da) | 2011-07-08 | 2019-07-01 | Aegerion Pharmaceuticals Inc | Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet |
CN102952067A (zh) * | 2011-08-30 | 2013-03-06 | 苏州欣诺科生物科技有限公司 | 用于蛋白质n端聚乙二醇修饰的吡哆醛衍生物、制备方法及其应用 |
WO2013033452A2 (en) | 2011-08-31 | 2013-03-07 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
WO2013040501A1 (en) | 2011-09-16 | 2013-03-21 | Pharmathene, Inc. | Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof |
UY34347A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de función dual para tratar trastornos metabólicos |
TWI593708B (zh) | 2011-09-26 | 2017-08-01 | 諾華公司 | 治療代謝病症之融合蛋白質 |
BR112014007247A2 (pt) | 2011-09-27 | 2017-03-28 | Novartis Ag | alisporivir para o tratamento de infecção por vírus da hepatite c |
WO2013056197A1 (en) | 2011-10-14 | 2013-04-18 | Alternative Innovative Technologies Llc | Degradation resistant hsp70 formulations and uses thereof |
MX342735B (es) | 2011-10-24 | 2016-10-07 | Halozyme Inc | Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo. |
US11707408B2 (en) | 2011-10-25 | 2023-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US10350139B2 (en) | 2011-10-25 | 2019-07-16 | Corning Incorporated | Pharmaceutical glass packaging assuring pharmaceutical sterility |
JP2015504038A (ja) | 2011-10-31 | 2015-02-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 低減した免疫原性を有するフィブロネクチン結合ドメイン |
CA2855770A1 (en) | 2011-11-17 | 2013-05-23 | Cebix Ab | Pegylated c-peptide |
RU2685867C2 (ru) | 2011-12-15 | 2019-04-23 | Алтернатив Инновейтив Текнолоджиз Ллц | Гибридные белки и белковые конъюгаты на основе белка теплового шока-70 (БТШ70) и способы их применения (варианты) |
US9447401B2 (en) | 2011-12-30 | 2016-09-20 | Halozyme, Inc. | PH20 polypeptide variants, formulations and uses thereof |
DK2809350T3 (en) | 2012-01-30 | 2019-01-28 | Arecor Ltd | STABILIZED Aqueous Antibody Preparations |
EP3311847A1 (de) | 2012-02-16 | 2018-04-25 | Atyr Pharma, Inc. | Histidyl-trna-synthetasen zur behandlung von autoimmun- und entzündungserkrankungen |
KR102057356B1 (ko) | 2012-02-27 | 2019-12-18 | 아뮤닉스 파마슈티컬스, 인크. | Xten 콘주게이트 조성물 및 그의 제조 방법 |
CN104136038A (zh) | 2012-02-29 | 2014-11-05 | 东丽株式会社 | 体腔积液抑制剂 |
EP2822575B1 (de) | 2012-03-03 | 2020-05-06 | ImmunGene, Inc. | Manipulierte antikörper-interferon-mutante fusionsmoleküle |
JP2015509980A (ja) | 2012-03-14 | 2015-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Hcv−hiv同時感染患者集団のhcv感染症を治療するための併用療法 |
JP2015512900A (ja) | 2012-03-28 | 2015-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法 |
EP2830663B1 (de) | 2012-03-30 | 2019-02-06 | Sorrento Therapeutics Inc. | Vollständig humane, an vegfr2 bindende antikörper |
LT2833905T (lt) | 2012-04-04 | 2018-07-10 | Halozyme, Inc. | Derinių terapija su hialuronidaze ir į naviką nukreiptu taksanu |
CA3175758A1 (en) | 2012-05-31 | 2013-12-05 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
PL2859017T3 (pl) | 2012-06-08 | 2019-07-31 | Sutro Biopharma, Inc. | Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania |
WO2013192596A2 (en) | 2012-06-22 | 2013-12-27 | Sorrento Therapeutics Inc. | Antigen binding proteins that bind ccr2 |
EP3135690A1 (de) | 2012-06-26 | 2017-03-01 | Sutro Biopharma, Inc. | Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung |
WO2014022515A1 (en) | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
CN104981254B (zh) | 2012-08-31 | 2018-05-22 | 苏特罗生物制药公司 | 含有叠氮基的经修饰的氨基酸 |
WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
EP2916835A4 (de) | 2012-11-12 | 2016-07-27 | Redwood Bioscience Inc | Verbindungen und verfahren zur herstellung eines konjugats |
US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
JP2016505528A (ja) | 2012-11-16 | 2016-02-25 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | タンパク質の化学修飾のためのピクテ−スペングラーライゲーション |
US20140205566A1 (en) | 2012-11-30 | 2014-07-24 | Novartis Ag | Cyclic nucleuoside derivatives and uses thereof |
US9383357B2 (en) | 2012-12-07 | 2016-07-05 | Northwestern University | Biomarker for replicative senescence |
EP2935311B1 (de) | 2012-12-20 | 2021-03-31 | Amgen Inc. | Apj-rezeptoragonisten und verwendungen davon |
CN103908660B (zh) * | 2013-01-05 | 2015-02-04 | 石药集团百克(山东)生物制药有限公司 | 一种聚乙二醇修饰的rhG-CSF药物组合物及其制备方法 |
WO2014120891A2 (en) | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
CN103113466B (zh) * | 2013-03-01 | 2015-06-03 | 中国科学院过程工程研究所 | 聚乙二醇修饰的重组人干扰素β-1b及制备方法 |
US10344060B2 (en) | 2013-03-12 | 2019-07-09 | Amgen Inc. | Potent and selective inhibitors of Nav1.7 |
EP2970433B1 (de) | 2013-03-13 | 2019-09-18 | Bioasis Technologies Inc. | Fragmente von p97 und verwendungen davon |
RU2535002C2 (ru) * | 2013-04-04 | 2014-12-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук | Средство коррекции отдаленных последствий нарушений сперматогенеза, вызванных цитостатическим воздействием |
CN105209054A (zh) | 2013-04-18 | 2015-12-30 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素-10治疗疾病和病症的方法 |
US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707154B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707153B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9717649B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9707155B2 (en) | 2013-04-24 | 2017-07-18 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9603775B2 (en) | 2013-04-24 | 2017-03-28 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9713572B2 (en) | 2013-04-24 | 2017-07-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9839579B2 (en) | 2013-04-24 | 2017-12-12 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9717648B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
EP3434277A1 (de) | 2013-06-17 | 2019-01-30 | Armo Biosciences, Inc. | Verfahren zur beurteilung der proteinidentität und -stabilität |
TW201534726A (zh) | 2013-07-03 | 2015-09-16 | Halozyme Inc | 熱穩定ph20玻尿酸酶變異體及其用途 |
ES2865473T3 (es) | 2013-07-10 | 2021-10-15 | Sutro Biopharma Inc | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
WO2015031673A2 (en) | 2013-08-28 | 2015-03-05 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
AU2014311432A1 (en) | 2013-08-30 | 2016-03-03 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
CA2926173A1 (en) | 2013-10-02 | 2015-04-09 | Novartis Ag | Insulin-like growth factor mimetics for use in therapy |
EP3055298B1 (de) | 2013-10-11 | 2020-04-29 | Sutro Biopharma, Inc. | Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung |
US20160235810A1 (en) | 2013-10-18 | 2016-08-18 | Novartis Ag | Methods of treating diabetes and related disorders |
RU2016122957A (ru) | 2013-11-11 | 2017-12-19 | Армо Байосайенсиз, Инк. | Способы применения интерлейкина-10 для лечения заболеваний и расстройств |
WO2015073727A1 (en) | 2013-11-13 | 2015-05-21 | Aequus Biopharma, Inc. | Engineered glycoproteins and uses thereof |
CN105744935B (zh) | 2013-11-27 | 2022-09-30 | 雷德伍德生物科技股份有限公司 | 肼基-吡咯并化合物及用于生成缀合物的方法 |
UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
WO2015130963A2 (en) | 2014-02-27 | 2015-09-03 | Xenetic Biosciences, Inc. | Compositions and methods for administering insulin or insulin-like protein to the brain |
WO2015187295A2 (en) | 2014-06-02 | 2015-12-10 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
CA2951391C (en) | 2014-06-10 | 2021-11-02 | Amgen Inc. | Apelin polypeptides |
BR112016029076B1 (pt) | 2014-06-12 | 2024-02-15 | Ra Pharmaceuticals, Inc | Polipeptídeo e composição compreendendo o mesmo para inibir a clivagem de c5 em um sistema celular |
US9765145B2 (en) | 2014-08-22 | 2017-09-19 | Sorrento Therapeutics, Inc. | Fully human anti-C-X-C chemokine receptor 3 (CXCR5) antibodies |
HUE043847T2 (hu) | 2014-08-28 | 2019-09-30 | Halozyme Inc | Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia |
CN107001438A (zh) | 2014-10-14 | 2017-08-01 | 阿尔莫生物科技股份有限公司 | 白细胞介素‑15组合物及其用途 |
ES2753391T3 (es) | 2014-10-14 | 2020-04-08 | Halozyme Inc | Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas |
EP3209320B1 (de) | 2014-10-22 | 2023-03-08 | Armo Biosciences, Inc. | Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden |
CN114805532A (zh) | 2014-10-24 | 2022-07-29 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
EP4282485A3 (de) | 2014-11-06 | 2024-01-17 | PharmaEssentia Corporation | Dosierungsplan für pegyliertes interferon |
US10046058B2 (en) | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
CN104491843B (zh) * | 2015-01-23 | 2017-09-12 | 石药集团百克(山东)生物制药有限公司 | 一种聚乙二醇修饰的rhG‑CSF活性药物组合物 |
SI3250230T1 (sl) | 2015-01-28 | 2022-01-31 | Ra Pharmaceuticals, Inc. | Modulatorji aktivnosti komplementa |
WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
CN107849108A (zh) * | 2015-03-03 | 2018-03-27 | 阿瓦隆生物制品有限公司 | 聚乙二醇化的il‑11的组合物和方法 |
US10711067B2 (en) | 2015-03-03 | 2020-07-14 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
US10167334B2 (en) | 2015-04-03 | 2019-01-01 | Xoma Technology Ltd. | Treatment of cancer using anti-TGF-BETA and PD-1 antibodies |
JP6525171B2 (ja) | 2015-04-13 | 2019-06-05 | 国立研究開発法人産業技術総合研究所 | 環状化サイトカイン及びその製法 |
ES2903448T3 (es) | 2015-05-01 | 2022-04-01 | Allysta Pharmaceuticals Inc | Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares |
KR20180020141A (ko) | 2015-05-28 | 2018-02-27 | 아르모 바이오사이언시스 인코포레이티드 | 암 치료에 사용되는 peg화된 인터류킨-10 |
WO2017024285A2 (en) | 2015-08-06 | 2017-02-09 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
CN108025040A (zh) | 2015-08-25 | 2018-05-11 | 阿尔莫生物科技股份有限公司 | 使用白介素-10治疗疾病和病症的方法 |
SG11201802180TA (en) | 2015-09-18 | 2018-04-27 | Univ Miyazaki | Long-acting adrenomedullin derivative |
WO2017059371A1 (en) | 2015-10-01 | 2017-04-06 | Amgen Inc. | Treatment of bile acid disorders |
US10935276B2 (en) | 2015-10-20 | 2021-03-02 | Steven Michalski | Air mixing device |
US11202819B2 (en) | 2015-12-08 | 2021-12-21 | Biomarin Pharmaceutical Inc. | Use of C-type natriuretic peptide variants to treat osteoarthritis |
AU2016370210A1 (en) | 2015-12-16 | 2018-06-21 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
KR20190026642A (ko) | 2016-01-29 | 2019-03-13 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
JP7148493B2 (ja) | 2016-08-01 | 2022-10-05 | ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー | 副甲状腺ホルモン受容体1(pth1r)抗体およびその使用 |
MX2019003543A (es) | 2016-09-28 | 2019-06-17 | Xoma Us Llc | Anticuerpos que se fijan al interleucina-2 y sus usos. |
CN110087668A (zh) | 2016-12-07 | 2019-08-02 | Ra制药公司 | 补体活性的调节剂 |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
AU2018219283B2 (en) | 2017-02-08 | 2022-05-19 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
NZ760116A (en) | 2017-06-22 | 2024-03-22 | Vertex Pharma | Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use |
KR102020995B1 (ko) | 2017-10-30 | 2019-09-16 | 한국코러스 주식회사 | 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법 |
WO2019133399A1 (en) | 2017-12-26 | 2019-07-04 | Becton, Dickinson And Company | Deep ultraviolet-excitable water-solvated polymeric dyes |
US11732016B2 (en) | 2017-12-27 | 2023-08-22 | Council Of Scientific & Industrial Research | Polypeptide exhibiting granulocyte-colony stimulating factor activity |
CN112135837A (zh) * | 2018-03-14 | 2020-12-25 | 勇·巴 | 聚乙二醇化抗冻蛋白及其制备和使用方法 |
JP2021519841A (ja) | 2018-03-30 | 2021-08-12 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | ペンダントクロモフォアを有する水溶性ポリマー色素 |
SG11202010430QA (en) | 2018-04-24 | 2020-11-27 | Amgen Inc | Method for making injectable pharmaceutical compositions |
US20190351031A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
KR102167755B1 (ko) | 2018-05-23 | 2020-10-19 | 주식회사 큐어바이오 | 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도 |
WO2020023300A1 (en) | 2018-07-22 | 2020-01-30 | Bioasis Technologies, Inc. | Treatment of lymmphatic metastases |
FI3849614T3 (fi) | 2018-09-11 | 2024-02-08 | Ambrx Inc | Interleukiini-2-polypeptidikonjugaatteja ja niiden käyttöjä |
US20220009986A1 (en) | 2018-10-19 | 2022-01-13 | Ambrx, Inc. | Interleukin-10 polypeptide conjugates, dimers thereof, and their uses |
US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
EP3902913A1 (de) | 2018-12-28 | 2021-11-03 | Catalyst Biosciences, Inc. | Modifizierte urokinaseartige plasminogenaktivatorpolypeptide und verfahren zur verwendung |
KR20210136014A (ko) | 2019-02-12 | 2021-11-16 | 암브룩스, 인코포레이티드 | 항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도 |
US10882954B2 (en) | 2019-04-11 | 2021-01-05 | Sunbio Inc. | Tertiary alkoxy polyethylene glycol and derivatives thereof |
JP7281140B2 (ja) * | 2019-04-15 | 2023-05-25 | 日油株式会社 | 生体関連物質とブロックポリマーとの結合体、および前記結合体を得るためのブロックポリマー誘導体 |
US11136353B2 (en) | 2019-04-15 | 2021-10-05 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof |
AU2021233909A1 (en) | 2020-03-11 | 2022-09-29 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and methods of use thereof |
WO2021188869A2 (en) | 2020-03-20 | 2021-09-23 | Amgen Inc. | Determination of free n-terminus of pegfilgrastim using an acid protease |
US20210355468A1 (en) | 2020-05-18 | 2021-11-18 | Bioasis Technologies, Inc. | Compositions and methods for treating lewy body dementia |
US20210393787A1 (en) | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
CA3190606A1 (en) | 2020-08-20 | 2022-02-24 | Ambrx, Inc. | Antibody-tlr agonist conjugates, methods and uses thereof |
US11602598B1 (en) * | 2020-08-27 | 2023-03-14 | Fresenius Kabi Deutschland Gmbh | Prefilled syringe with pegfilgrastim having optimized dose and methods related thereto |
CN112710826A (zh) * | 2020-11-17 | 2021-04-27 | 北京九强生物技术股份有限公司 | 一种提高试剂稳定性的包被和封闭方法 |
US11952461B2 (en) | 2021-03-22 | 2024-04-09 | Sunbio, Inc. | Siloxy polyethylene glycol and derivatives thereof |
KR20240004342A (ko) | 2021-04-03 | 2024-01-11 | 암브룩스, 인코포레이티드 | 항-her2 항체-약물 접합체 및 이의 용도 |
CN113214328B (zh) * | 2021-05-08 | 2022-06-28 | 宁波经济技术开发区弘翔生化科技有限公司 | 一种双水相体系以及基于双水相体系的单糖分离方法 |
EP4155349A1 (de) | 2021-09-24 | 2023-03-29 | Becton, Dickinson and Company | Wasserlösliche gelbe grünabsorbierende farbstoffe |
WO2024007016A2 (en) | 2022-07-01 | 2024-01-04 | Beckman Coulter, Inc. | Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives |
WO2024044327A1 (en) | 2022-08-26 | 2024-02-29 | Beckman Coulter, Inc. | Dhnt monomers and polymer dyes with modified photophysical properties |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1609546A (en) * | 1925-11-19 | 1926-12-07 | Petroleum Rectifying Co | Process of separating water from emulsions |
DE2047413C3 (de) * | 1970-09-26 | 1980-05-29 | F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) | Verfahren zur Herstellung von Peptiden in homogener Phase |
US4002714A (en) * | 1972-08-14 | 1977-01-11 | Fumio Usui | Method for producing a tapered pipe of reinforced synthetic resin |
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) * | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
DE2930542A1 (de) | 1979-07-27 | 1981-02-12 | Hoechst Ag | Neue insulinderivate und verfahren zu ihrer herstellung |
JPS57192435A (en) | 1981-05-20 | 1982-11-26 | Toyobo Co Ltd | Modified polypeptide |
DE3139483C2 (de) | 1981-10-03 | 1985-06-13 | Dr.-Ing. Rudolf Hell Gmbh, 2300 Kiel | Verfahren und Schaltungsanordnung zur Kontraststeigerung |
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
DE3380726D1 (en) * | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
JPS58225025A (ja) * | 1982-06-24 | 1983-12-27 | Nippon Chem Res Kk | 効力持続性組成物 |
WO1985003934A1 (en) | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
DE3572982D1 (en) * | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
JPS61227526A (ja) * | 1984-07-25 | 1986-10-09 | Chugai Pharmaceut Co Ltd | 新規なコロニー刺激因子 |
JPS6142558A (ja) | 1984-08-06 | 1986-03-01 | Matsushita Electric Works Ltd | アミノ樹脂成形材料 |
WO1986004605A1 (en) | 1985-02-08 | 1986-08-14 | Chugai Seiyaku Kabushiki Kaisha | Human granulocyte colony stimulating factor |
JPS62129298A (ja) | 1985-12-02 | 1987-06-11 | Chugai Pharmaceut Co Ltd | 新規ポリペプチド |
US5532341A (en) * | 1985-03-28 | 1996-07-02 | Sloan-Kettering Institute For Cancer Research | Human pluripotent hematopoietic colony stimulating factor |
US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
WO1987000056A1 (en) | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
ES8800982A1 (es) | 1985-07-05 | 1987-12-01 | Takeda Chemical Industries Ltd | Un metodo para producir la enzima superoxido-dismutasa modificada con derivados de polietilenglicol y triazina. |
US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
JPS62236497A (ja) | 1985-09-17 | 1987-10-16 | Chugai Pharmaceut Co Ltd | 顆粒球コロニー刺激因子活性を有する糖蛋白質の製造方法 |
JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
DK203187A (da) * | 1986-04-22 | 1987-10-23 | Immunex Corp | Human g-csf proteinekspression |
US6673347B1 (en) * | 1986-04-30 | 2004-01-06 | Gryphon Therapeutics | Polypeptide and protein derivatives and process for their preparation |
CA1283046C (en) | 1986-05-29 | 1991-04-16 | Nandini Katre | Tumor necrosis factor formulation |
US4791192A (en) * | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
JPS63126900A (ja) | 1986-06-26 | 1988-05-30 | Takeda Chem Ind Ltd | 化学修飾蛋白質 |
JPS63152393A (ja) * | 1986-07-03 | 1988-06-24 | Takeda Chem Ind Ltd | グリコシル誘導体 |
GR871067B (en) | 1986-07-18 | 1987-11-19 | Chugai Pharmaceutical Co Ltd | Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor |
EP0256843A1 (de) | 1986-08-11 | 1988-02-24 | Cetus Corporation | Expression von G-CSF, Muteine davon und deren Verwendung |
JPS6360938A (ja) | 1986-09-02 | 1988-03-17 | Meiji Milk Prod Co Ltd | 修飾組織型プラスミノ−ゲン活性化因子およびその製造方法 |
US4894226A (en) * | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
US5214132A (en) * | 1986-12-23 | 1993-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
US5362853A (en) * | 1986-12-23 | 1994-11-08 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
US5194592A (en) * | 1986-12-23 | 1993-03-16 | Kyowa Hakko Kogyo Co. Ltd. | Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor |
NO176799C (no) * | 1986-12-23 | 1995-05-31 | Kyowa Hakko Kogyo Kk | DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid |
JPH086063B2 (ja) | 1987-07-22 | 1996-01-24 | 日本ペイント株式会社 | 親水性表面処理剤及び処理方法 |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
CA1340810C (en) * | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
JP2958019B2 (ja) | 1988-05-06 | 1999-10-06 | 住友製薬株式会社 | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
NZ229098A (en) * | 1988-05-13 | 1992-10-28 | Amgen Inc | (bg-csf) bovine granulocyte colony stimulating factor, recombinant methods and pharmaceuticals |
US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
US5349052A (en) * | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
GB8824591D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
JPH04502011A (ja) | 1988-11-23 | 1992-04-09 | ジェネンテク,インコーポレイテッド | ポリペプチド誘導体 |
US6166183A (en) * | 1992-11-30 | 2000-12-26 | Kirin-Amgen, Inc. | Chemically-modified G-CSF |
ATE135370T1 (de) * | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
WO1990009798A1 (en) | 1989-02-24 | 1990-09-07 | Immunotherapeutics, Inc. | Immobilized cytokines |
US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
WO1991005798A1 (en) * | 1989-10-10 | 1991-05-02 | Amgen Inc. | Compositions and methods for treating or preventing infections in canine and feline animals |
JP2978187B2 (ja) | 1989-11-02 | 1999-11-15 | 日本ケミカルリサーチ株式会社 | 修飾スーパーオキサイドディスムターゼの製造法 |
JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
DE4009661C1 (de) | 1990-03-26 | 1991-03-07 | Aisa Automation Industrielle S.A., Vouvry, Ch | |
GB9107846D0 (en) | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
DE4014750A1 (de) * | 1990-05-08 | 1991-11-14 | Boehringer Mannheim Gmbh | Muteine des granulozyten-stimulierenden faktors (g-csf) |
US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
ES2128348T3 (es) * | 1990-10-17 | 1999-05-16 | Amgen Inc | Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular. |
US5252714A (en) * | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
US5124297A (en) | 1990-12-07 | 1992-06-23 | Amoco Corporation | Olefin polymerization and copolymerization catalyst |
CH682636A5 (de) * | 1990-12-21 | 1993-10-29 | Bucher Guyer Ag Masch | Verfahren zum selektiven Entfernen von Zucker aus Getränken. |
JP2864434B2 (ja) | 1991-01-18 | 1999-03-03 | サイナーゲン,インコーポレーテッド | 腫瘍壊死因子媒介疾患の治療方法 |
DE4105480A1 (de) | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
CA2288429C (en) | 1991-03-15 | 2006-04-25 | Synergen, Inc. | Pegylation of polypeptides |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
WO1993000109A1 (en) | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
US5281698A (en) * | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
US5197592A (en) * | 1991-08-05 | 1993-03-30 | Fmc Corporation | Wire frame idler roll support |
NZ244778A (en) * | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
US5589365A (en) * | 1991-11-29 | 1996-12-31 | Banyu Pharmaceutical Co., Ltd. | Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms |
JP3235855B2 (ja) | 1991-12-19 | 2001-12-04 | 住友製薬株式会社 | 細胞接着活性ペプチド及びその高分子修飾体 |
JP3387519B2 (ja) * | 1992-03-04 | 2003-03-17 | 株式会社日立製作所 | 情報記録再生方式及びデイスク状記録媒体 |
FR2692736B1 (fr) | 1992-06-23 | 1996-12-20 | Thomson Csf | Filtre radioelectrique de forte et moyenne puissance. |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
WO1994012219A2 (en) | 1992-11-25 | 1994-06-09 | Amgen Boulder Inc. | Modified insulin-like growth factors |
US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5589356A (en) | 1993-06-21 | 1996-12-31 | Vanderbilt University | Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement |
AU7113594A (en) * | 1993-06-21 | 1995-01-17 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
US5481571A (en) | 1993-11-12 | 1996-01-02 | Pacific Communication Sciences, Inc. | Method and apparatus for switching between radio frequency circuits |
US5795569A (en) * | 1994-03-31 | 1998-08-18 | Amgen Inc. | Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation |
CZ288926B6 (cs) * | 1994-03-31 | 2001-09-12 | Amgen Inc. | MGDF derivát, způsob jeho výroby a farmaceutický prostředek s jeho obsahem |
US5646113A (en) * | 1994-04-07 | 1997-07-08 | Genentech, Inc. | Treatment of partial growth hormone insensitivity syndrome |
US5935924A (en) * | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
US5661122A (en) * | 1994-04-15 | 1997-08-26 | Genentech, Inc. | Treatment of congestive heart failure |
WO1995032003A1 (en) | 1994-05-24 | 1995-11-30 | Amgen Boulder Inc. | Modified insulin-like growth factors |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
JP3708151B2 (ja) | 1994-12-15 | 2005-10-19 | 協和醗酵工業株式会社 | Peg化したヒト顆粒球コロニー刺激因子の定量法 |
US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
KR101441331B1 (ko) | 2013-07-19 | 2014-09-17 | 주식회사 슈프리마 | 광학식 지문 인식 장치 |
-
1994
- 1994-10-12 US US08/321,510 patent/US5824784A/en not_active Expired - Lifetime
-
1995
- 1995-02-08 CN CN2008101276757A patent/CN101381409B/zh not_active Expired - Lifetime
- 1995-02-08 CA CA002472085A patent/CA2472085A1/en not_active Abandoned
- 1995-02-08 DE DE69509628T patent/DE69509628T2/de not_active Expired - Lifetime
- 1995-02-08 CN CNB001309749A patent/CN1229388C/zh not_active Expired - Lifetime
- 1995-02-08 CA CA2307142A patent/CA2307142C/en not_active Expired - Lifetime
- 1995-02-08 DE DE69533556T patent/DE69533556T2/de not_active Revoked
- 1995-02-08 EP EP04015640A patent/EP1564219A1/de not_active Withdrawn
- 1995-02-08 IL IL11258595A patent/IL112585A/xx not_active IP Right Cessation
- 1995-02-08 JP JP51319196A patent/JP3177251B2/ja not_active Expired - Lifetime
- 1995-02-08 PT PT97117514T patent/PT822199E/pt unknown
- 1995-02-08 CN CNA2005101137680A patent/CN1896103A/zh active Pending
- 1995-02-08 NZ NZ281469A patent/NZ281469A/en not_active IP Right Cessation
- 1995-02-08 DE DE2002199044 patent/DE10299044I1/de active Pending
- 1995-02-08 EP EP95910233A patent/EP0733067B1/de not_active Expired - Lifetime
- 1995-02-08 AT AT95910233T patent/ATE179991T1/de active
- 1995-02-08 KR KR1019960703099A patent/KR100248111B1/ko not_active IP Right Cessation
- 1995-02-08 WO PCT/US1995/001729 patent/WO1996011953A1/en active IP Right Grant
- 1995-02-08 ZA ZA951008A patent/ZA951008B/xx unknown
- 1995-02-08 EP EP97117514A patent/EP0822199B1/de not_active Revoked
- 1995-02-08 IL IL134754A patent/IL134754A/en not_active IP Right Cessation
- 1995-02-08 AT AT97117514T patent/ATE277078T1/de active
- 1995-02-08 MX MX9602259A patent/MX9602259A/es active IP Right Grant
- 1995-02-08 EP EP10183858A patent/EP2392594A1/de not_active Withdrawn
- 1995-02-08 EP EP10180124A patent/EP2399930A1/de not_active Withdrawn
- 1995-02-08 DK DK95910233T patent/DK0733067T3/da active
- 1995-02-08 CN CN95191454A patent/CN1071760C/zh not_active Expired - Lifetime
- 1995-02-08 ES ES97117514T patent/ES2224197T3/es not_active Expired - Lifetime
- 1995-02-08 CA CA002178752A patent/CA2178752C/en not_active Expired - Lifetime
- 1995-02-08 ES ES95910233T patent/ES2131811T3/es not_active Expired - Lifetime
-
1996
- 1996-07-22 JP JP19257696A patent/JP3177449B2/ja not_active Expired - Lifetime
-
1997
- 1997-06-20 US US08/879,760 patent/US5985265A/en not_active Expired - Lifetime
-
1998
- 1998-07-31 HK HK98109573A patent/HK1008826A1/xx not_active IP Right Cessation
- 1998-07-31 HK HK98109570A patent/HK1008787A1/xx not_active IP Right Cessation
-
1999
- 1999-03-19 JP JP11076959A patent/JPH11310600A/ja active Pending
- 1999-06-16 GR GR990401601T patent/GR3030526T3/el unknown
- 1999-10-23 KR KR1019997009836A patent/KR100261030B1/ko not_active IP Right Cessation
-
2000
- 2000-02-27 IL IL13475400A patent/IL134754A0/xx unknown
-
2001
- 2001-03-26 US US09/817,725 patent/US7090835B2/en not_active Expired - Fee Related
-
2002
- 2002-10-01 JP JP2002288746A patent/JP2003155299A/ja not_active Withdrawn
- 2002-11-04 NL NL300106C patent/NL300106I2/nl unknown
-
2003
- 2003-01-29 LU LU91006C patent/LU91006I2/fr unknown
- 2003-04-10 JP JP2003106520A patent/JP2003327600A/ja active Pending
-
2005
- 2005-09-30 JP JP2005286189A patent/JP2006045243A/ja not_active Withdrawn
- 2005-09-30 JP JP2005286188A patent/JP2006077021A/ja not_active Withdrawn
-
2006
- 2006-04-26 US US11/411,321 patent/US7662933B2/en not_active Expired - Fee Related
-
2009
- 2009-12-16 US US12/639,398 patent/US8258262B2/en not_active Expired - Fee Related
-
2010
- 2010-06-14 JP JP2010134726A patent/JP5350330B2/ja not_active Expired - Lifetime
-
2012
- 2012-08-02 US US13/565,447 patent/US20120296072A1/en not_active Abandoned
-
2013
- 2013-03-19 US US13/847,290 patent/US20130189219A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69509628D1 (de) | N-terminal chemisch modifizierte protein-zusammensetzungen und methoden | |
DE69922958D1 (de) | Hcv hüllproteine partikel : verwendung für therapeutische impfung | |
ATE152172T1 (de) | Herstellung eines rekombinanten menschlichen interleukin-1-hemmers | |
ATE277081T1 (de) | Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten | |
ATE124997T1 (de) | Enzymatische entfernung einer aminoterminalen proteinsequenz. | |
ATE309360T1 (de) | Vaskularer endothelialer wachstumsfaktor 2 | |
NO894503L (no) | Uretan-beskyttede aminosyre-n-karboksyanhydrider. | |
DK0759067T3 (da) | Transformerende vækstfaktor alfa-H1 | |
DK485788A (da) | Kosmetisk praeparat | |
MX9200709A (es) | Activacion mejorada de proteinas recombinadas. activacion mejorada de proteinas recombinadas. | |
DE69737651D1 (de) | Cortistatin: neuropeptide, zusammensetzungen und methoden | |
SE9602822D0 (sv) | New receptor | |
SE8801723D0 (sv) | Fibronectin binding protein as well as its preparation | |
ATE270333T1 (de) | Von proteinen des hepatitis c-virus abgeleitete polypeptide und deren verwendung | |
ATE123056T1 (de) | Ancrod-proteine, ihre herstellung und verwendung. | |
SE9604439D0 (sv) | New receptor | |
ATE27822T1 (de) | Hexapeptid, verfahren zur herstellung und pharmazeutische zusammensetzungen hieraus. | |
ES2004438A6 (es) | Un metodo para producir una proteina trombolitica | |
ES8705466A1 (es) | Un metodo para la preparacion del factor nkbs regulador del cancer humano. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R431 | Request for term correction |
Free format text: PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/227/001 20020822 Spc suppl protection certif: 10299044 Filing date: 20021106 Expiry date: 20150209 Extension date: 20170826 |
|
R432 | Decision on term correction now final |
Free format text: PRODUCT NAME: PEGFILGRASTIM; REGISTRATION NO/DATE: EU/1/02/227/001 20020822 Spc suppl protection certif: 10299044 Filing date: 20021106 Expiry date: 20150209 Extension date: 20170826 |